BTIG Maintains Buy on Immunocore Hldgs, Raises Price Target to $91
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin maintains a Buy rating on Immunocore Hldgs (NASDAQ:IMCR) and raises the price target from $85 to $91.
August 11, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Justin Zelin maintains a Buy rating on Immunocore Hldgs and raises the price target from $85 to $91.
The news is directly about Immunocore Hldgs (IMCR). The maintained Buy rating and increased price target by BTIG analyst Justin Zelin is a positive signal for the stock, which could lead to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100